OS and event-free survival with uproleselan at 10 mg/kg in combination with chemotherapy in patients with AML. OS (A) and event-free survival (B) among those with R/R disease; OS (C) and (D) event-free survival among those age ≥60 years with newly diagnosed disease; and OS (E) among patients with R/R disease according to E-selectin ligand expression ≥10% and <10%. AML, acute myeloid leukemia; NA, not applicable; RP2D, recommended phase 2 dose.